The BrazIliaN Type 1 & 2 DiabetEs Disease Registry (BINDER) study observed that the typical treatment for T2D in Brazil includes biguanide, sulfonylureas, DPP4 inhibitors (DPP4i), SGLT2 inhibitors (SGLT2i), GLP-1 receptor agonist (GLP-1RA), and insulin. This evidence concerns the gene INS and type 2 diabetes mellitus.